Boehringer Ingelheim: cross-border access for the specialty portfolio

Quick orientation

Boehringer Ingelheim International GmbH is a German family-owned pharmaceutical company headquartered in Ingelheim am Rhein, with US operations based in Ridgefield, Connecticut. Boehringer Ingelheim's specialty footprint is anchored in cardiometabolic disease (Jardiance and the Lilly-co-marketed empagliflozin franchise, Trajenta, Glyxambi), respiratory and pulmonary fibrosis (Spiolto Respimat, Spiriva, Ofev for IPF and SSc-ILD), oncology (Giotrif in EGFR-mutant NSCLC; Vargatef in NSCLC), dermatology (Spevigo for generalized pustular psoriasis), and stroke prevention (Pradaxa).

Portfolio in cross-border NPP scope

Jardiance (empagliflozin, co-marketed with Eli Lilly)

SGLT2 inhibitor approved for type 2 diabetes, heart failure across the ejection-fraction spectrum, and chronic kidney disease. International requests for the US-distributed Jardiance specifically come from patients in MENA and India where the most recent CKD and HFpEF indications have not yet been added locally.

Ofev (nintedanib)

Tyrosine kinase inhibitor approved for idiopathic pulmonary fibrosis, systemic sclerosis-associated ILD, and chronic fibrosing interstitial lung diseases with progressive phenotype. US WAC at the standard 150mg twice-daily dose runs above $130,000 per year. Cross-border requests come predominantly from IPF and SSc-ILD patients in MENA and India where the locally registered indication is narrower than the FDA label.

Spevigo (spesolimab)

Anti-IL-36-receptor monoclonal antibody approved for generalized pustular psoriasis flares in adults and for prevention of GPP flares with subcutaneous maintenance dosing. International requests come from GPP patients in MENA and India where this rare severe dermatologic emergency has no other on-label therapy and where local registration has not happened.

Giotrif and Gilotrif (afatinib)

Second-generation irreversible EGFR-TKI approved for first-line EGFR-mutant metastatic NSCLC and for squamous-cell NSCLC after platinum chemotherapy. International requests come from NSCLC patients in MENA and India where the patient has failed first-generation EGFR-TKIs and where osimertinib resistance has emerged.

Pradaxa (dabigatran etexilate)

Direct thrombin inhibitor approved for stroke prevention in non-valvular atrial fibrillation, VTE treatment and prophylaxis, and pediatric VTE. Cross-border requests cluster around the pediatric VTE indication where the dose presentations may not be locally stocked.

Praxbind (idarucizumab)

Reversal agent for dabigatran-induced anticoagulation in emergency surgery or life-threatening bleeding. International requests are rare but acute: emergency-department use cases where the patient is on Pradaxa and the local hospital has not stocked the reversal agent.

Trajenta (linagliptin)

DPP-4 inhibitor approved for type 2 diabetes. International requests come from patients in MENA and India who specifically prefer linagliptin over other DPP-4 inhibitors for its renal safety profile.

Why patients route Boehringer Ingelheim products through cross-border NPP

Three patterns dominate. First, Ofev for IPF and SSc-ILD is a high-cost specialty therapy where MENA and India payer coverage is narrow. Second, Spevigo for generalized pustular psoriasis is too new globally for most non-US labels and the rare-severe-dermatology population has essentially no locally on-label alternative. Third, the Jardiance HFpEF and CKD indications are recent additions and not all MENA payers have added them. BI Cares and the Boehringer Ingelheim Patient Assistance Program are restricted to US residents.

Manufacturer engagement posture

Reserve Meds coordinates Boehringer Ingelheim-manufactured US product through DSCSA-compliant specialty wholesaler channels. We are not an authorized Boehringer Ingelheim distributor. All Reserve Meds orders are cash-pay at firm-quote pricing.

For Boehringer Ingelheim market access teams: Reserve Meds maintains structured demand visibility across cardiometabolic, pulmonary fibrosis, and dermatology rare-disease franchises. If your group is sizing pre-registration demand in MENA and India, we are open to a structured conversation under NDA.

Common cross-border destinations for the Boehringer Ingelheim portfolio

Ofev concentrates in tertiary pulmonology centers in the UAE, Saudi Arabia, India, and Egypt. Spevigo and the GPP franchise serves rare-dermatology centers across the Gulf and India. The cardiometabolic franchise (Jardiance, Trajenta) is broad across MENA and India. The oncology franchise (Giotrif) tracks oncology specialist concentration.

What Reserve Meds provides

For every Boehringer Ingelheim product order, Reserve Meds coordinates DSCSA chain-of-custody documentation; cold-chain validated logistics where required; country regulatory pathway expertise covering named-patient import approval, customs clearance, and any required physician declaration; and a single patient-facing coordinator. We do not replace the patient's treating physician. A US-licensed pharmacist reviews every prescription before dispensing.

Next step for patients

Patients or caregivers who have a treating physician's prescription for a BI product and want a firm quote can start a request below.

Start a request for a BI product

Next step for BI teams

If you are on the BI access, medical affairs, or international market access team and want to discuss coordinated named-patient program demand from MENA and India, reach us at [email protected]. We will share aggregated demand views under NDA.

Reserved for you.